Physalis peruviana L. (Cape gooseberry) is a plant widely cultivated in the Andean mountain in South America and its calyces are the main by-product of the harvest and commercialization of the fruits. Hypoglycemic activity was evaluated to the hydroethanolic extract and its fractions by glucose tolerance test. Since butanolic fraction exhibited hypoglycemic activity as well as the hydroethanolic extract, this fraction was microencapsulated in hypromellose phthalate (HPMCP) by the emulsification-evaporation method. Rutin was the major flavonoid in the whole extract and butanolic fraction. By using Plackett-Burman and Box-Behnken statistical experimental designs, were developed and optimized HPMCP-microparticles loaded with butanolic fraction. Optimized microparticles have an entrapment efficiency of 71% and yield of 64%, only 8% of release at acidic pH and significant hypoglycemic activity. Development and optimization of microencapsulated butanolic fraction of calyces from P. peruviana is an important contribution to improve its hypoglycemic activity as a promising therapeutic strategy.
INTRODUCTION
Physalis peruviana L. (Cape gooseberry) is a plant widely cultivated in the Andean mountain in South America since its fruits are consumed as raw, juices, desserts, jam and processed food (Puente et al., 2011) . The plant is an herbaceous, semiupright shrub known for its round, orange-colored fruit which is juicy with a pleasant smell and taste fruit and is enclosed in fivesepal calyx (Novoa et al., 2006) . P. peruviana fruits are the second most exported fruit from Colombia whereby its crops exceed the 950 ha/year and are produced more than 15.000 ton/year of fruits (AGRONET, 2018) .
In the recent years, P. peruviana has been the subject of many biological studies whence multiple pharmacological activities have been reported. For its leaves has been found antioxidant (Wu et al., 2005) and antidiabetic activity (Kasalia et al., 2013) . For its fruits, also has been antidiabetic activity (Mora et al., 2010) as well as inhibition of intestinal alfa amylase enzyme (Rey et al., 2015) , immunomodulatory and cytotoxic activity in HeLa and fibroblast cells (MierGiraldo et al., 2017) and anti-pterygium effect by inhibiting fibroblast growth (Pardo et al., 2008) . The calyces have been shown hepatoprotective effect (Toro et al., 2013) and antiinflammatory activity related to inhibition of the release of macrophage's proinflammatory cytokines (Martínez et al., 2010) and the inhibition of nitric oxide and prostaglandin E2 (Franco et al., 2014) .
P. peruviana calyces are the main by-product of the harvest and commercialization of the fruit and the study of its pharmacological properties and chemical composition is a great opportunity to give added value to this important crop. The previous investigation has been reported the presence of sucrose esters (Franco et al., 2014) and hydroxycinnamic acids (Vilaplana et al., 2014) as well as a large content of rutin (Quercetin 3-O-rutinoside) as the main flavonoid .
Rutin is an O-glycosylated flavonoid of which has been reported several biological effects, including antidiabetic activity related to the decreased of glycosylated hemoglobin, C-peptide, and malondialdehyde level (Stanley and Kamalakkanan, 2006) . In rodents diabetic by streptozotocin administration also has exhibit hepatoprotective effect in (Fernandes et al., 2010) . In vitro studies show that rutin potentiates insulin receptor kinase (Hsu et al., 2014) and stimulates both the Ca(2+) uptake in rat pancreatic islets (Kappel et al., 2013a) and the glucose uptake in the soleus muscle mediated by extracellular calcium and calciumcalmodulin-dependent protein kinase II (CaMKII) (Kappel et al., 2013b) . Being rutin the major flavonoid in P. peruviana calyces, these previous reports suggest its potential hypoglycemic/ antidiabetic activity.
In spite of the pharmacological properties of the vegetable extracts, some environmental and systemic condition could degrade the active metabolites of several extracts (Goppel and Franz, 2004; Thakur et al., 2011; Sipahli et al., 2017) , mainly O-glycosylated flavonoids as rutin (Plaza et al., 2014) . For this reason, microencapsulation has been employed for several vegetable extracts since this technique allows a target delivery, protection from enzymes or hydrolytic pHs, masking bitter tastes and improve extracts stability (Singh et al., 2010; Fang and Bhandari, 2010; Santos et al., 2017; Massoung-Bora et al., 2018) resulting in an improvement of the biological activity. Considering the flavonoid rutin as one of the active metabolites of the calyces of P. peruviana and its reported instability under acidic conditions, microencapsulation in a pH-sensitive polymer was chosen as a delivery system. Based on the above described, the aim of this work was to evaluate the hypoglycemic activity of the calyces of P. peruviana and to the development and to optimize a microparticulate delivery system that induces an increase on the hypoglycemic activity. For this, initially was determinate the hypoglycemic active fraction of the calyces of P. peruviana, then by a Plackett-Burman design was found the significant factors on microencapsulation process of the active fraction and later the microparticles were optimized using a Box-Behnken design. Finally, the hypoglycemic activity of the optimized microparticles was evaluated.
MATERIALS AND METHODS

Chemicals
PVA, glucose, and glibenclamide were obtained from Sigma-Aldrich®. Hypromellose phthalate (HPMCP) from Kerry®. Dichloromethane, ethyl acetate, butanol, acetic acid, and ethanol were purchased from Panreac®. Methanol was obtained from Mallinkrodt®. All organic solvents were of analytical reagent grade except for methanol which was HPLC grade and water used in all experiments was purified by Direct -Q system (Millipore®).
Plant material
The calyces of Physalis peruviana L. were collected in the region of Granada Cundinamarca (2450 masl), on June 2016. The fresh calyces were dried in an oven drying at a temperature of 40°C until constant weight, and ground in a knife mill. One specimen was stored in the Herbarium of the National University of Colombia (COL 512200).
Preparation of P. peruviana calyces extract and fractions
Hydroethanolic extract of P. peruviana was obtained by percolation according to previous reports (Cardona et al., 2017) . Drug: solvent ratio 1:15 and ethanol 70% during 72 hours. The hydroalcoholic extract was submitted to vacuum column chromatography over silica gel (Merck 60), employing solvents in increasing polarity (dichloromethane, ethyl acetate, butanol, and water), yielding three organic fractions and one aqueous fraction. The organic fractions were concentrated by a rotatory evaporator and the aqueous fraction was lyophilized. All fractions were stored at −4°C. Ethyl acetate (EFPP), butanol (BFPP) and water/ aqueous fractions (WFPP) were considered for further analysis while dichloromethane was not due to its low yield (less than 1%).
Rutin quantification
Quantification of Rutin in the extract, fractions, and microparticles was carried out by HPLC by a methodology previously developed and validated (Cardona et al., 2017) . Briefly, A Shimadzu® system (Shimadzu, Tokyo, Japan), consisting of an LC-6AD binary pump, SPD-M20A diode array detector (DAD), SIL-20A HT auto-sampler, DGU-20As in-line degasser, and software LCsolution® were used. The injections (10 μL) were carried out on a Phenomenex C-18 10 μm (150 × 3.9 mm) column conditioned in a Shimadzu® CTO-20A column oven equilibrated at 35°C, with detection at 350 nm. The gradient employed was: acidified methanol (0.5% acetic acid) (A) with acidified water (0.5% acetic acid) (B) as follows: 10-50% A (0-5 min), 50% A (5-10 min), 50-80% A (10-15 min) and 80% A (15-25 min).
Hypoglycemic activity
Animals
The animals were supplied by the Pharmacy Department of the National University of Colombia. Adult female Swiss ICR mice were employed for the evaluation of the hypoglycemic activity (90 animals, 7-10 weeks old, weighting of 30-35 g). The animals were acclimated under constant temperature conditions (22°C ± 1), 12-hour light/dark cycles, and ad libitum feed and water consumption one week before the bioassay. The bioassays were carried out in accordance with Guide for the Care and Use of Laboratory Animals (1996, published by National Academy Press, 2101 Constitution Ave. NW, Washington, DC 20055, USA). The local Research Ethics Committee (Act 07/2014 Faculty of Science) approved this study.
Glucose tolerance test
For hypoglycemic activity evaluation of the extract, fractions, and optimized microparticles, it was employed the glucose tolerance test. After 4 h of fasting, blood glucose levels (BGL) were measured and immediately were orally administered by gavage with each treatment. Thirty minutes after, all the animals were orally administrated with glucose (2000 mg/kg). BGL was measured (using equipment Accu-Chek Performa®) before glucose administration and 30, 60, and 120 minutes after. Glibenclamide was administered at 200 mg/Kg, for fraction selection assay, extract and fractions were administered at 500 mg/Kg as the maximum dose according to the internal criteria of our research group. For the most active fraction, hypoglycemic activity was evaluated at three different doses (100, 300, and 500 mg/Kg). For final test, active fraction was administered at 300 mg/ Kg (according to the results on dose-response evaluation) and the optimized microparticles were administered at equivalent of 300 mg/kg of the active fraction. In each group n = 6 mice.
Preparation of microparticles
Due to the low aqueous solubility of the rutin and butanol fraction of the ethanolic extract from calyces of P. peruviana (BFPP), the microparticles were prepared by an emulsificationsolvent evaporation method . HPMCP and BFPP were dissolved in a mixture of dichloromethane: ethanol (25:1). This organic phase was mixed with an aqueous phase that content PVA as a stabilizer and emulsified by agitation with Ultra-Turrax® T10 (IKA, Germany) according to the statistical experimental design. Once the emulsion was formed, the organic solvent was removed by constant stirring for 3 hours at room temperature. The obtained suspension was centrifuged at 25000 g for 8 minutes. The pellet was washed with distilled water 3 times. Finally, the pellet was lyophilized and the microparticles were obtained.
Characterization of the obtained microparticles
Yield
After the microparticles of each treatment were lyophilized, the microparticles obtained were weighed. The yield of the microencapsulation process was calculated according to equation 1. 
Morphological analysis and particle size
The shape of the particles obtained was observed by scanning electron microscopy (SEM). The dry microparticles were coated with gold and examined with a scanning electron microscope (FEI QUANTA 200) .
Particle size was determinate by analysis of SEM micrographs. Three hundred microparticles of each treatment were observed and measured employed ImageJ (NIH, Bethesda, MD) software.
Entrapment efficacy (%EE)
EE was evaluated by an indirect method. After the organic phase was evaporated, the aqueous phase was centrifuged for 15 minutes at 12000 g. An aliquot of the supernatant was taken, filtered through 0.22 μm membrane and the rutin content was measured by using HPLC.
The percentage entrapment efficacy (%EE) was calculated by equation 2: In vitro release profile assay BPFF release (using rutin as a marker) was evaluated. 1 mL of the release medium was added to 10 mg of optimized microparticles and aliquots were taken at 60, 120, 180, 240, 320 and 360 minutes for the quantification of rutin by HPLC method previously described. The first 2 hours pH 1.2 solution (HCl 0.1 N) was employed as release medium, after that time the medium was replaced by phosphate buffer pH 6.8. The release assay was carried out under constant rotary agitation at 37°C.
Statistical experimental designs
Plackett-Burman design
Plackett-Burman design was used to identify the significant factors on the entrapment efficacy of the active fraction by the emulsification-evaporation method. The parameters evaluated were: (A) concentration of the HPMCP; (B) concentration of PVA; (C) Organic phase percentage; (D) HPMCP: BFPP ratio, (E) volume of the aqueous phase; (F) stirring intensity and (G) and stirring time. Each factor was evaluated in two levels: high and low (Table 1) . Additionally, yield and particle size were calculated for each treatment. 
Optimization of BFPP microencapsulation in HPMCP
Box-Behnken design (BBD)
Once were identified the factors that influence the entra efficiency of the active fraction microencapsulation in HPMCP, the more suitable levels where chosen and Box-Behnken response surface methodology (RSM) was employed to find the optimal conditions to BFPP entrapment efficacy. For the experimental design, three factors (independent variable) were assayed at three levels: low (−1), medium (0) and high (+1). The number of experiments (N) required for the development of BBD was defined as N = 2k (k−1) + C 0 , (where k is number of factors and C 0 is the number of central points). For this research, the BBD used was composed of 15 experiments, which 12 treatments and 3 central points (table 2) .
Statistical analysis
The software Minitab® (version 17 State College, PA, USA) was used to propose the experimental designs, data analysis, and model building of the optimization process. GraphPad Prism® software (version 7, San Diego, CA, USA) was employed for analysis data of glucose tolerance test. 
RESULT AND DISCUSSION
The content of rutin in P. peruviana calyces extract and fractions
According to HPLC-DAD quantification, rutin content in the obtained extract was 14.54 µg/mg dry extract. In the fractions obtained, rutin was only found in the butanolic fraction (22.00 µg/mg dry extract). Hypoglycemic activity of P. peruviana calyces extract and fractions The hypoglycemic effect was evaluated by glucose tolerance test which is often employed as screening to several plant extracts. This test allows following the BGL at specific points on the time after an oral glucose overload as well as the global effect on time by the area under the curve (AUC mg/dl*min) analysis (Andrikopoulos et al., 2008) . Hypoglycemic activity of the extract and fractions of calyces form P. peruviana by glucose tolerance test is present in Figure 1 . Is possible to note that hydroethanolic extract of P. peruviana has a significant hypoglycemic effect and this activity is maintained only by the butanolic fraction (BFPP). In the first 60 minutes, the BGL decrease by BFPP is even greater than those presented by the whole extract. This fact suggests that the active hypoglycemic compounds of calyces from P. peruviana extract are in the butanolic fraction similar to reported to other plants (Borar et al., 2011; Toma et al., 2015; Ibrahim and Islam, 2017) . According to previous reports that identify rutin as major flavonoid in the hydroethanolic extract of calyces from P. peruviana and the evidence of hypoglycemic effect of this compound and its role in the glucose homeostasis by different mechanisms like secretagogue of insulin and stimulating of glucose uptake in muscle (Kappel et al., 2013a; , is possible to relate this flavonoid to the observed effect.
Before microencapsulation, a dose-response study of BFPP was carried out (Figure 2) . The results suggest that the hypoglycemic activity of the BFPP is dose-dependent and that 300 mg/Kg is the lowest active dose (in the range studied). Based on these results, BFPP was chosen to develop a microparticulate system as a delivery system with hypoglycemic activity.
Microencapsulation of BFPP in HPMCP
Rutin is extremely labile to acidic hydrolysis, as well as the other O-glycosylated flavonoid. This fact as well as its poor aqueous solubility, contribute to its low bioavailability (Sharma et al., 2013) and therefore to a limited pharmacological activity. Considering rutin as one of the secondary metabolites responsible for the hypoglycemic effect presented by BFPP, polymer hypromellose phthalate (HPMCP) was chosen for microparticles development. HPMCP is pH sensitive polymer soluble at pH higher than 5.5 widely employed in formulations of drugs labile to gastric conditions (Qi and Ping, 2004; Rassu et al., 2014; Singh et al., 2015) .
For the development of HPMCP BFPP-loaded microparticles, initially was determine the factors that influenced the entrapment efficacy of the rutin (as marker) content in BFPP. For this, it was using the Plackett-Burman experimental design which has been successfully employed as screening design for formulation development (Vanaja and Shobha, 2007) . For this, seven factors were evaluated at two levels (Table 1) which were selected based on previous results of our research group. Yield values ranged between 31 and 62% and all were considering microparticles (sizes between 1 and 7 µm).
According to the ANOVA analysis (Table 3) , the model was significant (p < 0.05) to entrapment efficiency of BPFF. For the statistical analysis, only the significant factors were employed while the other factors were grouped in the error term. The concentration of HPMCP (%), concentration of PVA (%) and organic phase (%) were the factors with the greatest effect on entrapment efficacy of BPFF. These factor at their low level had a positive effect on the response variable and it was further optimized by Box-Behnken design. Optimization According to Plackett-Burman design, for optimization four factors were kept constant HPMCP: BFPP ratio (3:1), volume of aqueous phase (100 mL), stirring speed (14500 rpm) and stirring time (5 min). The concentration of HPMCP (%), concentration of PVA (%) and organic phase (%) were optimized at three levels (Table 4) .
Experimental statistical designs have been widely used for microencapsulation process (Paulo and Santos, 2017) for both, screening and optimization. Box-Behnken are experimental designs for response surface methodology successfully employed for optimization of process and formulation of drug delivery systems. The Box-Behnken experimental design employed in this study consisted of 15 treatments, three of them were central points (Table 5) . According to ANOVA, the F-value of the model (15.15) implies that the model was significant (<0.05) ( Table 6 ). In this design, only the concentration of PVA was a significant factor as well as the interactions PVA x PVA and organic phase x organic phase. None of the 2-way interactions were significant in the experimental design. The analysis of variance calculated for the coefficient of determination R 2 and coefficient of determination adjusted values of 0.9646 and 0.9009 respectively. Lack of fit is not significant which indicates that the model fits well with the data. Response surface plots are shown in Figure 3 . 
where EE = Entrapment efficacy (%); A = Concentration of PVA (%); B = Concentration of HPMCP (%); C = Organic phase (%).
Finally, Minitab 17 software was employed to determine the optimum values of the factors for maximum entrapment efficiency as follows: 1.54% for Concentration of HPMCP; 0.47% for a concentration of PVA and 3% for organic phase. The predicted value of encapsulation efficiency was 72.5%. To verify the prediction of the model, six batches of microparticles of BFPP were prepared with the optimal conditions. The experimental value of encapsulation efficiency was 71.3 ± 0.27%; yield of 64.1 % and 4.3 µm as average size. Experimental entrapment efficiency was not significantly different from the predicted value. Release profile was evaluated for the optimized microparticles (Figure 4 ) in order to verify the gastroprotective effect of the HPMCP polymer. In the first 120 minutes at pH 1.2, similar to gastric pH, only 6.5% of BFPP (measured as rutin) was released. This release can be explained by burst effect of BFPP located on the surface of the microparticles (Rizi et al., 2011) . Once the release medium change to pH 6.8, BFPP release increase until reaching the 100% at 360 min (6 hours). This profile is similar to those reported to other HPMCP delivery systems (Prasad et al., 2013; Chung et al., 2014) suggesting an effective acid pH protection to BFPP. 
Hypoglycemic activity of BFPP free and microencapsulated
The effect of the microencapsulation on the hypoglycemic activity of BFPP was evaluated by the glucose tolerance test (Figure 5 ).
Microencapsulated BFPP exhibit higher decrease of the BGL that free BFPP. And in spite of that difference was statistically significant only at t = 60 min (p < 0.05), the AUC results show that over time, there is a greater BGL decrease in the animals treated that microencapsulated BFPP that those treated with free BFPP (p < 0.05) similar to previous reports to other hypoglycemic extracts and compounds (Chime et al., 2014; Sharma and Mazumder, 2014; Zhao et al., 2014) . These results evidence the influence of microparticulate delivery systems on the pharmacological activity since it allows overcome some problems of several drugs as poor solubility and pH or enzymatic degradation, among others (Singh et al., 2010) . This fact has been reported for different drugs encapsulated with HPMCP as insulin, tymol, and vaccines (Qi and Ping, 2004; Rassu et al., 2014; Singh et al., 2015) . Considering the flavonoid rutin as one of the compounds responsible of hypoglycemic activity of BFPP and taking into account its instability at acidic conditions, development, and optimization of HPMCP BFPP-loaded microparticles is an important contribution to improve the hypoglycemic activity of the butanolic fraction of calyces from P. peruviana.
CONCLUSIONS
In this study, it was demonstrated the hypoglycemic activity of the hydroethanolic extract of calyces from P. peruviana.
Its butanolic fraction, rich in rutin, identified as the most active. By using statistical experimental designs were developed and optimized HPMCP BFPP-loaded microparticles that improved the hypoglycemic effect of butanolic fraction of calyces from P. peruviana. The developed microparticles are a promising delivery system of a hypoglycemic fraction from calyces of P. peruviana.
